Turn Biotechnologies Acquires ARMMs Vesicular Technology to Increase Access to Tissue Targets for its Epigenetic Reprogramming Therapies
ARMMs brings precision medicine through targeted, non-viral vesicular delivery Synergy of ARMMs and eTurna™ LNP platforms means company can deliver broad range of larger, more varied cargoes – including gene editors, proteins and RNA-based therapies...